ATE528017T1 - Antimikrobiellen verbindungen und formulierungen - Google Patents

Antimikrobiellen verbindungen und formulierungen

Info

Publication number
ATE528017T1
ATE528017T1 AT01910034T AT01910034T ATE528017T1 AT E528017 T1 ATE528017 T1 AT E528017T1 AT 01910034 T AT01910034 T AT 01910034T AT 01910034 T AT01910034 T AT 01910034T AT E528017 T1 ATE528017 T1 AT E528017T1
Authority
AT
Austria
Prior art keywords
hydrogen atoms
group
lipophilic
amino acids
cationic
Prior art date
Application number
AT01910034T
Other languages
English (en)
Inventor
John Svendsen
Bengt Haug
Istvan Marko
Oystein Rekdal
Merete Skar
Wenche Stensen
Morten Stroem
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Application granted granted Critical
Publication of ATE528017T1 publication Critical patent/ATE528017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01910034T 2000-03-09 2001-03-09 Antimikrobiellen verbindungen und formulierungen ATE528017T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005703.4A GB0005703D0 (en) 2000-03-09 2000-03-09 Compounds
PCT/GB2001/001035 WO2001066147A2 (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations

Publications (1)

Publication Number Publication Date
ATE528017T1 true ATE528017T1 (de) 2011-10-15

Family

ID=9887297

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910034T ATE528017T1 (de) 2000-03-09 2001-03-09 Antimikrobiellen verbindungen und formulierungen

Country Status (10)

Country Link
US (3) US7232803B2 (de)
EP (2) EP2338522A1 (de)
JP (3) JP2004514644A (de)
AT (1) ATE528017T1 (de)
AU (2) AU3761601A (de)
CA (1) CA2400410C (de)
DK (1) DK1263471T3 (de)
GB (1) GB0005703D0 (de)
NO (1) NO334230B1 (de)
WO (1) WO2001066147A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
EP1328658A2 (de) * 2000-06-22 2003-07-23 San Diego State University Foundation Rekombinationsmodulatoren und verfahren zu ihrer herstellung und verwendung
NO20031818D0 (no) * 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
WO2007127457A2 (en) * 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
JP5322108B2 (ja) * 2006-07-10 2013-10-23 ペーベーアードライ ビオメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗菌ペプチド
GB0724953D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
GB0724951D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
US9139355B2 (en) * 2008-04-18 2015-09-22 Medline Industries, Inc. Glove packaging having antimicrobial barrier
US9409946B2 (en) 2008-06-17 2016-08-09 Peptisyntha Peptide manufacturing process
GB0818074D0 (en) * 2008-10-02 2008-11-05 Lytix Biopharma As Treatment of biofilms
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2456465B1 (de) * 2009-07-21 2023-09-06 Udo Bogner Endoperoxidhaltiges materialsystem mit anpassung des zerfalls und anwendungen
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
WO2012092934A1 (en) 2011-01-06 2012-07-12 Bionor Immuno As Monomeric and multimeric immunogenic peptides
US9320698B2 (en) * 2011-05-11 2016-04-26 Escape Therapeutics, Inc. Peptide tyrosinase inhibitors and uses thereof
RU2014131370A (ru) * 2012-01-09 2016-02-27 Юниверсити Оф Тромсё Терапевтические соединения, содержащие бор
WO2013157871A1 (ko) * 2012-04-18 2013-10-24 대한민국(관리부서:농촌진흥청장) 다이펩타이드 유도체를 활성 성분으로 함유하는 농업용 작물 보호제
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
TWI577697B (zh) * 2013-11-28 2017-04-11 國立清華大學 耐高鹽及抗蛋白之抗菌胜肽及其製造方法
EP3071591B1 (de) 2014-01-22 2021-05-05 Agency For Science, Technology And Research Antimikrobielle peptidomimetika
EP4007359B1 (de) 2016-08-11 2025-09-17 Kyocera Corporation Ran-assistierte ratenanpassung
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN110938112A (zh) * 2019-12-10 2020-03-31 倪京满 脂肪酸修饰的超短序列抗菌肽类似物及其应用
CN110950932B (zh) * 2020-01-09 2023-04-18 福州大学 一种修饰肽的制备及其应用
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
CN113248572B (zh) * 2021-04-30 2023-04-11 重庆理工大学 一种抗多重耐药菌环肽及其应用
EP4646423A1 (de) * 2023-01-05 2025-11-12 Amicoat AS Peptidsyntheseverfahren mit sterisch gehindertem tri-tert-butyltryptophan (tbt)-rest

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) * 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
JP3009718B2 (ja) * 1990-10-01 2000-02-14 日本合成化学工業株式会社 新規ペプチド、その製造法及び用途
JP2771068B2 (ja) * 1991-03-13 1998-07-02 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
DE69220397T2 (de) * 1991-03-13 1997-10-02 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
JP3173858B2 (ja) * 1991-04-24 2001-06-04 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
DE69223844T2 (de) * 1991-04-24 1998-04-16 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
JP3173857B2 (ja) * 1991-04-24 2001-06-04 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5885782A (en) * 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
EP0838472A4 (de) * 1995-06-21 2000-02-02 Asahi Chemical Ind Peptide, die an low-density-lipoproteine binden
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US5948889A (en) 1996-05-21 1999-09-07 Case Western Reserve University Compositions and methods for screening antimicrobials
DE19818802A1 (de) * 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen
ES2182521T3 (es) * 1998-05-18 2003-03-01 Upjohn Co Mejoramiento de la actividad de agentes antibacterianos de oxazolidinona mediante derivados de arginina.
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
GB0005702D0 (en) 2000-03-09 2000-05-03 Alpharma As Method
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
US20030059827A1 (en) * 2001-03-13 2003-03-27 Cayetano Gonzalez Engineered protein binding domains and methods and systems for their design and use
US7291698B2 (en) * 2001-09-04 2007-11-06 Stephen Eliot Zweig Synthetic substrate for high specificity enzymatic assays

Also Published As

Publication number Publication date
WO2001066147A2 (en) 2001-09-13
US20120108520A1 (en) 2012-05-03
CA2400410A1 (en) 2001-09-13
US20100267621A1 (en) 2010-10-21
WO2001066147A3 (en) 2002-04-11
EP1263471A2 (de) 2002-12-11
US9115169B2 (en) 2015-08-25
JP5554810B2 (ja) 2014-07-23
US7232803B2 (en) 2007-06-19
US8048852B2 (en) 2011-11-01
US20030195144A1 (en) 2003-10-16
JP5747100B2 (ja) 2015-07-08
GB0005703D0 (en) 2000-05-03
JP2012229254A (ja) 2012-11-22
NO20024218L (no) 2002-11-05
DK1263471T3 (da) 2012-02-06
CA2400410C (en) 2013-06-11
AU3761601A (en) 2001-09-17
EP2338522A1 (de) 2011-06-29
NO20024218D0 (no) 2002-09-04
NO334230B1 (no) 2014-01-13
JP2004514644A (ja) 2004-05-20
EP1263471B1 (de) 2011-10-12
JP2014196302A (ja) 2014-10-16
AU2001237616B2 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ATE528017T1 (de) Antimikrobiellen verbindungen und formulierungen
BR0012243A (pt) Triflúor butenos nematocidas
ATE402164T1 (de) Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
NO20035327D0 (no) Biologisk aktive metylen-blått derivater
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
DK0696270T3 (da) 4-Aminofluorbenzamider og deres anvendelse som cytotoksiske promedikamenter
NL300283I1 (nl) Alfa- en bèta-aminozuur-hydroxyethylamino-sulfonamiden die toepasbaar zijn als retrovirale-prothease-remmers.
DK0623627T3 (da) Sulfonamidderivater
ATE444756T1 (de) Zusammensetzungen umfassend komplexe von tocopherolphosphatderivaten
ATE196913T1 (de) Neuartige peptidderivate
PT813542E (pt) Inibidores de proteases retrovirais hidroxietilamino sulfonamoda aminoacido
ES2243579T3 (es) Derivados de pirazolopirideno.
ATE201195T1 (de) Tricyclische verbindungen
DE60221508D1 (de) Aminosäurederivate als hiv-protease-inhibitoren
BR0109598A (pt) Inibidores de quinase de proteìna tricìclicos
NO303783B1 (no) Substituerte aminofosfonatderivater og farmas°ytiske preparater derav
NO20002548D0 (no) Nye substituerte dimere forbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem
BRPI0415123A (pt) uso de l-butilftalida e respectiva composição farmacêutica
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
ID25478A (id) Agonis 5-ht1f
MXPA02011234A (es) Nuevas bases de oxidacion 2,5-diaminopiridina utiles para el tinte de las fibras queratinicas.
DE50104724D1 (de) Neue 1,4-diamino-2-alkenyl-benzol-derivate und diese verbindungen enthaltende färbemittel
DK0410278T3 (da) Reninhæmmende aminooligohydroxyderivater
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties